Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide

Internal Medicine

Volumn 51, Issue 17, 2012, Pages 2375-2378

  Yamamoto, Sunao ^a   Okada, Yosuke ^a   Mori, Hiroko ^a   Fukumoto, Seiji ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fibroblast growth factor 23; Osteomalacia; Saccharated ferric oxide

Indexed keywords

25 HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR 23; IRON SACCHARATE; PHOSPHORUS;

ADULT; ARTICLE; BONE SCINTISCANNING; CASE REPORT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FEMUR NECK FRACTURE; GLOMERULUS FILTRATION RATE; HIP PAIN; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; KIDNEY TUBULE ABSORPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; RADICAL HYSTERECTOMY; UTERUS MYOMA; VITAMIN D DEFICIENCY;

ABSORPTIOMETRY, PHOTON; ADULT; ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; GLUCARIC ACID; HEMATINICS; HUMANS; OSTEOMALACIA; PHOSPHORUS; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84867786610     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7450     Document Type: Article

References (12)

1. Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr 61: 99-102, 1983.
2. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 45: 431-439, 1998.
3. Hori M, Shimizu Y, Fukumoto S. Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152: 4-10, 2011.
4. Bringhurst FR, Demay MB, Krane SM, Kronenberg HM. Bone and mineral metabolism in health and disease. In: Harrison's Principles of Internal Medicine. 17th ed. Fauci AS, Braunwald E, Kasper DL, et al, Eds. McGraw-Hill, New York, 2008: 2365-2377.
5. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94: 2332-2337, 2009.
6. Kirschbaum BB. Aggregation of renal brush border membranes by concanavalin A and heavy metals. Toxicol Appl Pharmacol 64: 10-19, 1982.
7. Sanai T, Oochi N, Okada M, Imamura K, Okuda S, Iida M. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. J Lab Clin Med 146: 25-29, 2005.
8. Imamura K. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. Comparative study on 3 iron preparations. Fukuoka Igaku Zasshi 75: 316-326, 1984.
9. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ven trolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494-498, 2000.
10. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.
11. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45: 814-816, 2009.
12. Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42: 1235-1239, 2008.